

CITATION REPORT

List of articles citing

Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone nave prostate cancer

DOI: 10.1016/j.urolonc.2019.05.017
Urologic Oncology: Seminars and Original Investigations, 2019, 37, 688-695.

Source: <https://exaly.com/paper-pdf/71917777/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Balancing efficacy and financial toxicity in the management of metastatic castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2019 , 13, 404-405	1.2	
20	WITHDRAWN: Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone for newly diagnosed multiple myeloma ineligible for stem cell transplantation. <i>Leukemia Research</i> , 2020 ,	2.7	
19	Advanced Prostate Cancer: Treatment Advances and Future Directions. <i>Trends in Cancer</i> , 2020 , 6, 702-715	5.5	42
18	Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer. <i>Cancer Management and Research</i> , 2020 , 12, 4369-4377	3.6	
17	Recent progress in treating advanced prostate cancer. <i>Current Opinion in Oncology</i> , 2020 , 32, 210-215	4.2	9
16	Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance. <i>BMC Cancer</i> , 2021 , 21, 35	4.8	3
15	Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis. <i>Frontiers in Public Health</i> , 2021 , 9, 608375	6	1
14	How I Treat Metastatic Hormone-Sensitive Prostate Cancer?. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021 , 42, 100-107	0.2	
13	An up-to-date evaluation of abiraterone for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1227-1234	4	1
12	Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 658331	5.3	2
11	A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1685-1728	4	1
10	Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in , or ?. <i>Pharmacogenomics</i> , 2021 , 22, 809-819	2.6	1
9	Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e326-e333	3.3	1
8	Prognostic Factors in Hormone-sensitive Prostate Cancer Patients Treated With Combined Androgen Blockade: A Consecutive 15-year Study at a Single Japanese Institute. <i>In Vivo</i> , 2021 , 35, 373-384	2.3	2
7	Systemic therapy in patients with genitourinary cancers during the COVID-19 pandemic. <i>Cancer Research Statistics and Treatment</i> , 2020 , 3, 354	0.3	1
6	Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.. <i>Value in Health</i> , 2022 , 25, 796-802	3.3	0
5	Hormone-Negative Metastatic Prostate Cancer: A Presentation of 110 Cases in a Urology Center in the City of Douala, Cameroon. <i>Open Journal of Urology</i> , 2022 , 12, 83-97	0.2	

4	Treatment of patients with metastatic hormone-sensitive prostate cancer: a systematic review of economic evaluations. <i>Clinical Genitourinary Cancer</i> , 2022 ,	3.3	○
3	The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer: A Systematic Literature Review with Application to the Canadian Context. <i>Current Oncology</i> , 2022 , 29, 3393-3424	2.8	○
2	Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis. 2022 , 11, 1021-1030		○
1	Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study.		○